Doctor Lothar Roessig
Asklepios BioPharmaceutical, Inc.,, Research Triangle Park (United States of America)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Safety and efficacy of a phase 1 clinical gene therapy trial in patients with advanced heart failure using a rationally designed cardiotropic AAV vector targeting protein phosphatase inhibitor-1
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: Chronic heart failure - treatment 5
